Reviewer's report

**Title:** Efficacy of Alogliptin in Type 2 Diabetes Treatment: A Meta-analysis on Randomized Double Blind Controlled Studies

**Version:** 1  **Date:** 17 November 2012

**Reviewer:** marc rendell

**Reviewer's report:**

Major compulsory revisions The authors must explain the clear differences between the Japanese studies and the American and European studies. They need to account for the obvious heterogeneity.

They must explain why the HbA1c lowering meta results were much more weighted by the Japanese studies.

There has to be a metaanalysis of adverse events including the skin effects which are well documented with alogliptin and the incidence of pancreatitis.

Minor revisions There are grammatical errors in several places.

**Level of interest:** An article of limited interest

**Quality of written English:** Needs some language corrections before being published

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I have been an investigator on several alogliptin studies other than that no competing interests.